The latest global marketing information and policy interpretation of tucatinib

Tucatinib (Tucatinib) is a highly selective HER2 tyrosine kinase inhibitor, mainly used to treat HER2-positive advanced or metastatic breast cancer, especially for patients with brain metastases. The drug was developed by Seattle Genetics in the United States and has been approved for marketing in many countries and regions. As a triple therapy combined with capecitabine and trastuzumab, it has shown significant clinical advantages in extending progression-free survival and overall survival. At present, tucatinib is not yet available in mainland China, and domestic patients who need to use it must obtain it through overseas medical channels.

In terms of international marketing, tucatinib was approved by the U.S. FDA in 2020 and was subsequently approved in Canada, the European Union, the United Kingdom, Japan and other places for the treatment of patients with advanced breast cancer who have received multiple anti-HER2 regimens. Of particular note is that the drug's efficacy against central nervous system metastasis has been verified in clinical trials, making it one of the first targeted drugs for brain metastasis of HER2-positive breast cancer. The launch of tucatinib is also regarded as an important breakthrough in the field of precision treatment of HER2-positive breast cancer.

However, in mainland China, as the registration and approval process has not yet been completed, tucatinib has not yet been introduced into the domestic market for sale, and therefore cannot be included in the national medical insurance directory. For domestic patients, this means that they need to obtain the drug through overseas purchasing agents, overseas hospitals or cross-border direct mail of drugs. At the same time, because they are not covered by medical insurance, all costs must be borne at their own expense, which is a certain financial burden for some families, especially when the original drugs are expensive.

In terms of price, the original drug tucatinib (150 mg In contrast, generic drugs are already on the market in overseas markets, such as the 150 mg × 60 tablet version produced by a Lao pharmaceutical factory. The price is only about more than 2,000 yuan, which greatly lowers the threshold for drug use. This generic drug is highly consistent with the original drug in terms of drug ingredients and therapeutic effects, making it an alternative choice for some patients. In the future, if tucatinib is successfully launched in China and included in medical insurance, it may further improve the treatment accessibility for patients with HER2-positive breast cancer.

Reference materials:https://www.drugs.com/